Additional 2: Table S2.

Mean Fluorescence Intensity (MFI) of monocyte-derived cells stimulated with or without EVs shed by CD105+ CSCs and CD105- TCs. (DOCX 14 kb

Additional 1: Table S1.

Mean Fluorescence Intensity (MFI) of monocyte-derived cells cultured in presence or absence of renal cancer cells (CD105+ CSCs and CD105- TCs). (DOCX 13 kb

Additional 3: Figure S1.

EVs characterization. A. Representative size distribution of EVs shed by CD105+ CSCs and CD105- TCs obtained using NanoSight LM10 instrument equipped with the nanoparticle tracking analysis (NTA) 2.0 analytic software. B. Representative cytofluorimetric analysis performed by Guava easyCyte Flow Cytometer of EVs shed by CD105+ CSCs and CD105- TCs and analyzed with InCyte software. The following markers were evaluated: CD44, CD105, ι5 integrin, ι6 integrin, CD73, CD29, CD90 and CD146. (DOCX 451 kb

Additional file 1: Figure S1. of The effects of glomerular and tubular renal progenitors and derived extracellular vesicles on recovery from acute kidney injury

Renal cell proliferation in IRI-mice treated with Gl-MSCs-derived EVs. (A) Quantification of BrdU-positive cells/high power field (HPF) was performed in renal sections of IRI mice injected with vehicle alone (IRI-CTL), 400 × 106 EVs produced by Gl-MSCs (IRI-Gl-MSC-EV), 400 × 106 EVs produced by Gl-MSCs and obtained by floating process (IRI-Gl-MSC-EV-float), 400 × 106 EVs produced by Gl-MSCs and treated with RNase (IRI-RNase-Gl-MSC-EV), and in sham-operated SCID mice. ANOVA with Dunnett’s multiple comparison test was performed, (* p <0.05). (B) Representative micrographs of BrdU staining preformed on section of kidneys 2 days after IRI and treatments injection. Original magnification: ×40. (DOCX 135 kb